Kidney and cardiovascular outcomes SURPASS-4 kidney composite HR 0.58, slower eGFR decline (-1.4 vs -3.6 mL/min/1.73m2/yr), UACR -6.8% vs +36.9%
Pain Conditions That Respond to Peptide Therapy Peptide therapy shows promise across a diverse range of pain presentations
Regular exercise further aids in reducing pain and inflammation
The main limitation is absorption
[1] Preclinical Evidence: What the Animal Studies Show The body of animal research on BPC-157 is, by any measure, remarkably consistent
Studies exploring tendon healing, muscle injury models, and angiogenesis pathways have contributed to a growing body of literature, but this research has not progressed to human clinical trials, and BPC-157 is not approved by the FDA for any human or veterinary use